外源性脉络膜新生血管抑制剂的研究进展

Progress on exogenous inhibitors for choroidal neovascularization

脉络膜新生血管 (choroidalneovascularization ,CNV)是许多致盲眼病的主要病理改变 ,虽然临床上已采用激光光凝术、光动力疗法、经瞳孔温热疗法、放射疗法以及手术等针对CNV的治疗方法 ,但均有其局限性。随着对CNV发病机制的了解 ,一些具有潜在治疗价值的新生血管抑制剂涌出 ,为临床防治CNV相关疾病带来了新希望。

Choroidal neovascularization (CNV) is seen in age-related macular degeneration (AMD),presumed ocular histoplasmosis,pathological myopia and trauma.The currently accepted treatment modalities for CNV comprise laser photocoagulation,photodynamic therapy,transpupillary themotherapy (TTT),radiotherapy and surgery,etc.These approaches can offer short-term benefit to certain subgroups of patients,but are associated with significant adverse effects.Moreover,since they fail to address the underlying stimuli for blood vessel growth,these treatments are associated with high rates of persistent and recurrent disease accompanied by an increased frequency of severe visual loss.With the further understanding of the development of CNV,a number of angiostatic agents with potential therapeutic value have been found.It would be helpful for the prevention and treatment of the CNV-related diseases.